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study. Age distribution at diagnosis resembled an ‘M-shaped’ pattern with peaks
at 18 to 30 years (18%) and 50 to 70 years (17%) of age. The RLH (12.2%)
and Castle Hill Hospital (6.2%) had highest recruitment. The most prevalent
history of comorbidities before ITP were hypertension (16.7%), depression/anx-
iety (5.0%), diabetes (4.4%) osteoarthritis (4.1%) and arterial thromboembolism
(4.0%). The cohort’s median platelet count around diagnosis was 23.0 x109/L
([IQR 7-61 years]; 56.1% had platelet count <30 x109/L). Of those who received
treatment within 3 months of ITP diagnosis, 96.9% had 1st line treatment
[including prednisolone (86.1%) IVIg (34.3%), Anti-D (2.5%)], 19.8% had 2nd
line treatment [including rituximab (6.3%); splenectomy (1.8%) and others (<1%
to 4%)], and 11.9% had blood product transfusion [(platelet (8.8%), red blood
cells (4.7%)]. Throughout the entire cohort history, common treatments were
prednisolone (70.3%), IVIg (39.2%), splenectomy (12.8%), romiplostim
(9.24%), Anti-D (6.5%) and eltrombopag (6.1%), whereas 19.5% had no treat-
ment. For those with platelet counts <50 x109/L and bleed within 3 months of
diagnosis, there was a significant association with use of both 1st and 2nd line
treatment. A similar pattern of treatment was found for platelet counts ≥50
x109/L but to a lesser extent. Bleed from the respiratory system (e.g. haemop-
tysis), gastrointestinal system (exc. oral) and obstetric/gynaecological-related
ones were associated with receiving transfusion (including platelet). The medi-
an time from ITP diagnosis to having a splenectomy was 1.4 (IQR 0.5-3.9)
years; 77.1% were diagnosed below the age of 50. Fifteen individuals had this
procedure within 3 months of diagnosis, of which 60% were before 2010. Over
the last 2 decades there has been a decrease in the overall number of splenec-
tomies carried out [and in relation to the year that the splenectomised patients
were diagnosed (1990-99: 30.1%; 2000-09: 12.7%)], and for those diagnosed
within the last five years, 4.4% had this procedure. The same time periods saw
increased use of newer therapeutic agents (figure).
Figure 1.
Summary/Conclusions: Patients with low platelet and bleeding within the 1st
three months of ITP diagnosis were likely to receive both 1st and 2nd line treat-
ment options. Notable, is the decline of splenectomy as 2nd line treatment,
while there are different drug options available. It would be important to increase
the cohort size, including expanding internationally, to obtain more treatment
data on higher number of patients who received 2nd line treatment options and
long-term follow up data.
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EFFICACY AND SAFETY OF RIVAROXABAN FOR NON-VALVULAR ATRIAL
FIBRILLATION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT
S Ali*, LA Wakefield, K Saja
National Health Service, London, United Kingdom
Background: Patients with atrial fibrillation and severe renal impairment (CrCL
<30ml/min) were excluded from the ROCKET-AF study and, indeed, most of
the seminal phase 3 DOAC studies in atrial fibrillation. However, the summary
of product characteristics states that rivaroxaban may be used at a reduced
dose of 15mg OD for anti-coagulation management of atrial fibrillation in
patients with severe renal impairment (CrCl 15-29 ml/min). This recommenda-
tion was solely based on pharmacokinetic analyses and has not been validated
in a clinical study.
Aims: Assess safety and efficacy of rivaroxaban (15mg OD) in patients with
atrial fibrillation and severe renal impairment (CrCl 15 – 29 ml/min). The primary
safety point is occurrence of bleeding complications.
Methods: Retrospective cohort analysis of 30 patients with non-valvular atrial
fibrillation and severe renal impairment who were commenced on rivaroxaban
(15mg OD) in our anti-coagulation clinic between October 2012 and March
2015. Medical notes were reviewed and general practitioners were contacted
by telephone or fax. Information collected included age, weight, CHA2DS2-
Vasc and HAS-BLED scores, baseline blood investigations (CrCl, FBC, LFT
and clotting screen) and where available blood investigations at the time of the
bleeding event. 
Results: A total of 30 patients were retrospectively followed up for a minimum
of 10 months. The majority of patients were female (83.3%) with a median age
and weight of 89.5 years and 54 kilograms respectively. Median CHA2DS2-Vasc
score was 5, giving an estimated annual stroke risk of 6.7%, and approximately
76% of patients had a HAS-BLED score ≤2. Creatinine clearance was calculated
using the Cockcroft-Gault formula, and the median CrCl was 26.39 ml/min. During
the follow up period, 11 patients died (37%), one of whom died of massive gas-
trointestinal bleeding after being switched from rivaroxaban to warfarin due to
worsening renal function. The cause of death for one patient could not be
obtained, however there were no documented deaths due to rivaroxaban as a
primary or contributing cause. A total of 6 rivaroxaban related bleeding events
were identified with two events occurring in one patient. Bleeding sites included
nasal (epistaxis), gastro-intestinal and genitourinary tracts but there were no inci-
dents of intracranial haemorrhage or major bleeding as defined by the Interna-
tional Society on Thrombosis and Haemostasis. A patient who discontinued
rivaroxaban due to haematuria later developed acute limb ischemia requiring
embolectomy. Although compliance to treatment could not be assessed, a further
patient developed an ischemic stroke whilst on rivaroxaban.
Summary/Conclusions: Clinically relevant bleeding events occurred in
approximately 17% of our small cohort of very elderly patients with severe
renal impairment receiving rivaroxaban (15mg) as anti-coagulant therapy for
non-valvular atrial fibrillation. The event rate is almost identical to that in the
Rocket-AF study (16.7%) and there were no major bleeding events. Our find-
ings indicate that the use of rivaroxaban in this group of patients is feasible
and relatively safe.
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ORAL DIRECT ANTICOAGULANTS IN THE TREATMENT OF NONVALVULAR
ATRIAL FIBRILLATION. RESULTS OF THE DAILY CLINICAL PRACTICE
B Perez Villardon1,*, AM Garcia Bellon2, C Jimenez Rubio1, A Rubio Alcaide1,
L Perez Benito1, MA Ramirez Marrero2, M De Mora Martin2, E De Teresa Galvan3
1Cardiology, Hospital Comarcal Axarquia, Velez-Malaga, 2Cardiology, Hospital
Regional Carlos Haya, 3Cardiology, Hospital Clinico Universitario Virgen de la
Victoria, Malaga, Spain
Background: Atrial fibrillation (AF) is the most common arrhythmia. It leads to
significant morbidity and mortality. The new oral anticoagulants (NOAC) rep-
resent an improvement compared with standard treatment (vitamin K antago-
nists (AVK)) in the prevention of thromboembolic complications in patients with
non-valvular AF. 
Aims: The aim of this study is to analyse the clinical characteristics of the
patients (p) anticoagulated with NOAC and compared these with those taking
AVK, as well as to assess their effectiveness and safety. The primary study
outcome was the composite of stroke, systemic embolism, pulmonary
embolism, myocardial infarction or death (MACE). The primary safety outcome
was major haemorrhage.
Methods: We studied 688 p with a diagnosis of NVAF between November-
2011 and November-2014. We made a prospective analysis, with a median
follow-up of 14 months.
Results: A total of 688 p were included with a mean age of 73.4±7.9 in the
AVK group vs 73.9±8.3 in the NOAC group (p=0.432). In the NOAC group,
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hypertension was significantly more common (82.3% vs 92.2%, p<0.001), with
more frequent history of heart failure (15.3% vs 30.4%, p<0.001), and more
history of stroke or transient ischemic attack (10% vs 15.9%, p=0.022). Mean
scores for thromboembolic and bleeding risk indices are shown in Table 1.
Table 1.
SCORE ACENOCOUMAROL NOAC p
CHADS2 1.9±1.0 2.3±1.1 P<0.001
CHA2DS2VASc 3.5±1.3 3.9±1.5 P<0.001
HASBLED 1.3±0.7 1.4±0.7 P=0.086
The primary outcome occurred in 12 p receiving AVK (2.9%) and 11 p receiving
NOAC (4.1%) (p=0.413) (HR acenocoumarol vs NOAC 1.737; IC 95%: 0.760-
3.969, p=0.190). MACE were more common in patients with poor INR control
(58.3% vs 41.8%, p=0.037). In the univariate analysis, the factor associated
with MACE in the AVK group was the poor INR control (4.009 (1.266-12.696),
p=0.018), showing the sex female category a strong trend to be a protective
factor (0.228 (0.050-1.043), p=0.057). In the NOAC group, valvulopathy ≥mod-
erate (3.840 (1.166-12.652), p=0.027) and renal insufficiency (7.197 (1.743-
29-772), p=0.006) were significantly associated with MACE. The rate of major
bleeding was 3.51% with AVK, as compared with 0.6% per year in the group
that received NOAC (17 events -4.1% >vs. 2 events, 0.7%, p=0.009) (figure 1;
HR acenocoumarol vs NOAC 0.252; IC 95%: 0.058-1.101, p=0.067). In the
univariate analysis, the factors associated with bleeding in the AVK group were
age ≥75 years (3.187 (1.028-9.882), p=0.045) and HASBLED score (2.106
(1.072-4.136), p=0.031). The rate of intracranial bleeding was 1.02% with AVK
compared with 0.34% per year in NOAC group (5 events – 1.2% vs 1 event –
0.4%, p=0.248). There were no significantly differences in the rates of gastroin-
testinal bleeding (1.02% with AVK vs 0.94% per year, p=0.902) neither minor
bleeding (4.88% with AVK vs 3.51% per year, p=0.309). There was a signifi-
cantly higher rate of discontinuation with AVK (17.14% vs 6.68% per year,
p<0.001).
Figure 1.
Summary/Conclusions: Patients with NVAF anticoagulated with NOAC have
higher embolic risk than those that receive acenocoumarol. No differences
were found in efficiency. Patients anticoagulated with NOAC show a trend to
lower bleeding risk. In the multivariate analysis, the predictors of events in the
acenocoumarol group were the male category, poor INR control, ≥75 years,
anemia and HASBLED score. The predictors of events in the NOAC group
were valvulopathy≥moderate, renal insufficiency and anaemia.
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SWITCH FROM VKA, LMWH OR FONDAPARINUX TO DOACS IN THE
CLINICAL PRACTICE
F Cortiula*, U Venturelli, A Bertone, G Barillari
University Hospital of Udine, Center for Hemorrhagic and Thrombotic Diseases,
Udine, Italy, Udine, Italy
Background: New oral anti-coagulant drugs (NOACs) are largely used both in
AF (Atrial Fibrillation) and in VTE (Venous Thromboembolism) and, due to their
important advantages over older drugs, many patients have been switched
from VKA (Vitamin K antagonists), LMWH (Low Molecular Weight Heparin) or
Fondaparinux to NOACs. Current recommendations by scientific society sug-
gest switching from VKAs to NOACs according to the INR test result. Regarding
how to switch from Fondaparinux or LMWH to NOACs the suggested wash out
period is 24 hours.
Aims: Evaluate safety and efficacy of switching anticoagulant therapy from old
to new anticoagulant drugs without monitoring the INR. Safety outcomes were
major and minor bleeding rate. Effectiveness outcomes were VTE events. We
also evaluate the tolerability of the new treatment.
Methods: We switched patients, affected by AF or DVT, from VKAs or LMWH
or Fondaparinux to NOACs regardless from the INR. We follow current recom-
mendations for switching from LMWH and Fondaparinux; we applied to the
VKAs-DOACs switch the same schedule prescribed by current guidelines for
bridging therapy from VKAs to LMWH. Therefore, we began the NOACs treat-
ment after 24 hours since the last previous anticoagulant intake, if the patient
has been switched from LMWH, Fondaparinux or Acenocumarol. We began
the NOACs treatment after 48 hours if Warfarin was the patient’s therapy. We
checked the platelet count and the Creatinine Clearance collecting these lab-
oratory measurements within 30 days before the end of VKA treatment. We
collected outcomes measures until 30 days from the switch. Data are presented
as mean±standard deviation (SD). 
Results: We enrolled in the present study 603 patients: 458 have been
switched to NOACs from VKAs, 101 from LMWH and 44 patients from Fonda-
parinux. 179 patients were affected by AF and 424 by VTE. Thirty days after
the switching 99% of the patients were still on NOACs. Three patients com-
plained about nausea, dyspepsia and abdominal pain. Two of them came back
to VKAs and one patient change Rivaroxaban with Apixaban, without further
side effects. Two patients reported minor bleedings: gingival hemorrhage and
hematuria. One of them remained on NOACs treatment and another switch to
acetylsalicylic acid. There were no VTE recurrence and no bleedings in the
whole cohort.
Table 1.
Summary/Conclusions: Safety and efficacy of switching anticoagulant therapy
in our center are really satisfying compared to the studies that closely monitored
INR to adjust anticoagulant therapy switching, suggesting that monitoring INR
may not be routinely needed for the switch. Further studies are needed to con-
firm these findings.
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HIGH HEMOGLOBIN CONCENTRATIONS AND RISK OF THROMBOSIS:
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Background: Patients with polycythemia vera are known to have an increased
risk for thrombotic events. This effect has also been observed among those
with high as well as low concentrations of hemoglobin (Hgb) in the general
population. However many of the earlier studies lack sufficient clinical data to
account for underlying disease or causes of high Hgb.
Aims: To assess whether high concentrations of Hgb is an independent risk
factor for thrombotic events.
Methods: Hgb measurements and baseline characteristics were obtained from
participants in the Reykjavik-AGES study at enrollment in 2002. The Reykjavik-
AGES study, a nationwide screening study of 5755 elderly individuals, includes
thorough medical history, physical examination, and blood measurements. Life-
time incidents of thrombotic events were recorded up to 2015 in the Icelandic
National Health Service and linked to the participants of the study through the
National Registry. Primary outcomes of arterial and venous thrombosis were
considered separately 10 years before and after enrollment. Hgb measure-
ments at enrollment were used to determine exposure, both as a continuous
variable in steps of 10g/L and stratified into five strata (<130, 130-144,145-
159,160-175 and >175g/L for men and <120, 120-134,135-149,150-159,
>160g/L for women). Men with Hgb concentrations of 120-144g/L and women
with Hgb concentration of 120-134g/L were used as reference. Cox proportional
hazard regression was used for the statistical analyses and adjusted for con-
founders (gender, age, body mass index (BMI), diabetes mellitus, smoking,
hypertension, and statin use) in three different models.
Results: Analysis of Hgb concentration as a continuous variable in steps of 10
g/L revealed increased risk of arterial and venous thrombosis with increasing Hgb
concentration (hazard ratio (HR) 1.06 95% confidence interval (CI) [1.04-1.09]
p<0.001 and HR 1.08 95% CI [1.05-1.106] p<0.001). Adjustment for confounders
revealed a reverse effect (HR 0.92 95% CI [0.89-0.94] p<0.001 and HR 0.89 95%
CI [0.87-0.92] p<0.001). After excluding anemic patients (Hgb <130g/L for men
and <120g/L for women) there was however, no association (Table 1). Crude
analysis, using stratified Hgb levels, revealed increased risk of arterial and venous
thrombosis associated with high Hgb (Hgb: 160-175g/L for men and 150-159g/L
for women. HR 1.10 95% CI [1.02-1.20] p=0.02 and HR 1.17 95% CI [1.07-1.29]
p<0.001). After adjusting for gender, age, and BMI, this association was no longer
evident. There was however marginally increased risk of venous thrombosis in
those with slightly higher Hgb concentrations than the reference group (Hgb: 145-
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